3 completed, 2 active not recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow CNV: new trials by email Literature Review of CNV trials Research Report on CNV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
| Reinterpretation of CNV With Unknown Significance: a 5-year Retrospective Analysis reinterpretation of CNV - Genetic Disease, CNV | Completed | Central Hospital, Nancy, France | 282 | 2019-01-01 | 2020-10-05 | |
| Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration Efalizumab, Ranibizumab - Age Related Macular Degeneration, AMD | Phase 1 | Withdrawn | Vitreous -Retina- Macula Consultants of New York | 2008-03-01 | 2015-07-07 | |
| Evaluation of Retinal Structure With High Resolution Optical Coherence Tomography (OCT) Examination with an OCT device - Macular Edema, CNV | Completed | Sebastian Wolf | 700 | 2007-01-01 | 2023-11-29 | |
| Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration Combretastatin A-4 phosphate, Combretastatin A-4 Phosphate - Combretastatin A4 Phosphate, Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 8 | 2003-05-01 | 2017-12-06 |
Macular Degeneration (4) · Choroidal Neovascularization (3) · Eye Diseases (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Wet Macular Degeneration (2) · Genetic Diseases, Inborn (1) · Macular Edema (1)
Choroid Diseases (3) · Eye Diseases (3) · Metaplasia (3) · Neovascularization, Pathologic (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Retinal Degeneration (3) · Retinal Diseases (3) · Uveal Diseases (3) · Eye Diseases, Hereditary (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Macular Degeneration (1)
Ranibizumab (2) · Restraint, Physical (1) · aflibercept (1) · efalizumab (1) · fosbretabulin (1)
AbbVie (2) · Central Hospital, Nancy, France (1) · Johns Hopkins University (1) · Sebastian Wolf (1) · Vitreous -Retina- Macula Consultants of New York (1)
United States (4) · France (2) · Canada (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Jason S Slakter, MD (1) · Quan D Nguyen, MD, MSc (1) · Sebastian Wolf, MD PhD (1) · Sebastian Wolf, MD, PhD (1)
PMID 19217019, PMID 21087958, PMID 23316779, PMID 33074373, PMID 37221613